Keyword: Seattle Genetics
Seattle Genetics and Astellas scored their approval for Padcev nearly three months early, but that quick OK didn’t surprise analysts, who pointed to high unmet need in metastatic bladder cancer.
Just a week after posting strong data at SABCS, Seattle Genetics has nabbed the coveted FDA breakthrough label for its drug.
The pivotal trial linked the tyrosine kinase inhibitor to reduced risk of progression and death in patients with and without brain metastases.
Immunomedics has had a long and troubled road in the past few years that has included losing much of its C-suite after an FDA rejection.
The case centers on linker technology used in antibody-drug conjugates (ADCs) including Daiichi’s AstraZeneca-partnered DS-8201.
The data tee Seattle Genetics up to file for FDA approval of a TKI inhibitor it paid $614 million to acquire last year.
Astellas and Seattle Genetics’ antibody-drug conjugate is at it again. With Merck’s Keytruda, the med shrank 71% of bladder tumors, new data show.
The phase 2 success keeps Hal Barron’s group on track to file for approval in multiple myeloma by the end of the year.
Chinook Therapeutics raised $65 million to do for kidney disease what precision medicine has done for cancer. It aims to be in the clinic by 2021.
Scott Gottlieb goes back to biotech investing; Seattle Genetics taps first CCO; Affimed parts with CSO; and CSL Behring poaches former Biogen exec.
